The ruling reinforces the clear path for the U.S. Food and Drug Administration to issue a final decision on the amended New Drug Application (NDA) for YUTREPIA.
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/16/2024 | Sector Outperform | Scotiabank | ||
| 8/19/2024 | Outperform → Strong Buy | Raymond James | ||
| 8/16/2024 | $27.00 | Outperform | Raymond James | |
| 7/11/2024 | $310.00 → $321.00 | Overweight → Equal-Weight | Morgan Stanley | |
| 6/25/2024 | Perform | Oppenheimer | ||
| 2/12/2024 | $213.00 → $215.00 | Sell → Neutral | Goldman | |
| 2/5/2024 | $330.00 | Outperform | Leerink Partners | |
| 1/5/2024 | $18.00 → $28.00 | Buy | Needham |
Scotiabank initiated coverage of Liquidia Technologies with a rating of Sector Outperform
Raymond James upgraded Liquidia Technologies from Outperform to Strong Buy
Raymond James initiated coverage of Liquidia Technologies with a rating of Outperform and set a new price target of $27.00
GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v
MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The
MORRISVILLE, N.C., June 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) ("Liquidia" or the "Company") today announced the appointment of Rajeev Saggar, M.D., to the position of Chief Medical Officer. In this role, Dr. Saggar will oversee all aspects of research, clinical development, medical affairs, and regulatory affairs for Liquidia, assuming responsibilities on July 18, 2022. Roger Jeffs, Chief Executive Officer of Liquidia, said: "We are excited to add a leader of Dr. Saggar's caliber to our team as we prepare for the launch of YUTREPIA™ (treprostinil) inhalation powder upon receipt of final FDA approval. His expertise and credibility in treating patients across a wid
Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - Liquidia Corp (0001819576) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4/A - Liquidia Corp (0001819576) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
MORRISVILLE, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2024 financial results on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corpora
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023. "I'm proud of the close to 1,300 Unitherians who have contributed to yet another record revenue quarter and reaching a $3 billion annual revenue run rate in the third quarter," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of our stellar revenue performance, 2025 marks the start of a multi-year cascade of clinical data reads and r
United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 30, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and
10-Q - Liquidia Corp (0001819576) (Filer)
8-K - Liquidia Corp (0001819576) (Filer)
8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)
SC 13G/A - Liquidia Corp (0001819576) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)
Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)U.S. Supreme Court rejected final appeal of ‘793 patent decision, marking victories with respect to three patents originally asserted final and not subject to further appealStrengthened balance sheet by raising approximately $100 million in additional capital MORRISVILLE, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financi
MORRISVILLE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET. Access to the live webcasts will be available to investors and other interested parties via Liquidia's website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of each presentation will be available on Liquidia's website for at least 30 days following the event. About Liquidia CorporationLiquidi
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company's operations during a fireside chat session at the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. The session will take place on Tuesday, November 12, 2024, from 2:45 p.m. to 3:20 p.m., Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 1
United Therapeutics (NASDAQ:UTHR) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 2 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 1 0 0 2M Ago 0 1 0 0 0 3M Ago 1 2 1 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $336.78, a high estimate of $400.00, and a low estimate of $240.00. Observing a 13.18% increase, the curre
HC Wainwright & Co. analyst Andrew Fein maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $300 to $400.
United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 5 years by 20.86% on an annualized basis producing an average annual return of 33.79%. Currently, United Therapeutics has a market capitalization of $14.76 billion. Buying $1000 In UTHR: If an investor had bought $1000 of UTHR stock 5 years ago, it would be worth $4,326.61 today based on a price of $332.63 for UTHR at the time of writing. United Therapeutics's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga